Macrogenics

GSK's antibody-drug conjugate (ADC) GSK5764227, licensed from Hansoh Pharma, received FDA breakthrough status for treating relapsed or refractory extensive-stage small-cell lung cancer (SCLC). Early clinical evidence shows promise, with significant disease control in heavily pre-treated patients. GSK aims to accelerate development, highlighting the aggressive nature and poor prognosis of SCLC.

GlobalData evaluates drug development phases and approval likelihood using historical data. Trastuzumab duocarmazine, targeting HER2-negative cancers, is under development by Byondis, which focuses on precision medicines for cancer and autoimmune diseases.

Adenosine antagonists market growth driven by R&D in neurodegenerative diseases, oncology, and cardiovascular disorders. Innovations in formulation and delivery systems enhance efficacy and safety, increasing adoption. Key companies include Arcus Biosciences, Corvus Pharmaceuticals, Portage Biotech, Palobiofarm, iTeos Therapeutics. Promising drugs like Etrumadenant, Ciforadenant, PORT-6, and Inupadenant are in various clinical trial phases.

POD1UM-304 trial results show retifanlimab + chemotherapy significantly improves median overall survival in NSCLC patients to 18.1 months vs. 13.4 months with placebo + chemotherapy (HR: 0.75; P=0.0042). Retifanlimab was well-tolerated, with no new safety issues identified.

DelveInsight's HER2+ Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2032 report details historical and forecasted epidemiology, market trends in the US, EU5, and Japan. Key companies include Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, and Daiichi Sankyo. Therapies like SHR-A1811, Cinrebafusp alfa, and BI-1607 are highlighted. Regulatory approvals for KN026 and Enhertu are noted, with market growth expected due to increasing prevalence and pipeline product launches.

Incyte to present new oncology data at 2024 ASH Annual Meeting, including late-breaking results from the Phase 3 inMIND study on tafasitamab in follicular lymphoma. The company will also host a virtual analyst and investor event on December 12, 2024, to discuss key data presentations.

MacroGenics to release Q3 2024 financial results on Nov 5, hosting a conference call at 4:30 pm ET. Register via provided link for call details. Webcast available on the Investor Relations section of the website.

Macro­Gen­ics sells breast can­cer drug rights for up to $75 mil­lion.

The ADC market, driven by technological advancements and personalized medicine, is expected to reach ~USD 26 billion by 2030 with a CAGR of ~14%. North America leads due to high cancer incidence and strong biopharmaceutical sector. Key players include F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, and Pfizer Inc. The market is dynamic, influenced by regulatory frameworks and innovation in linker technologies and payloads.

MacroGenics presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo) at ESMO, showing encouraging antitumor activity with a 6-month landmark rPFS rate and ORR. Patients remained on vobra duo through a median of 6 doses, extending treatment duration compared to Phase 1. The company expects mature median rPFS data by early 2025 and will host an investor call on September 16, 2024.